Skip to Content
US Videos

3 Dividend Growth Stocks for Your Radar

Gilead, Intel, and Citigroup look to maintain consistent growth and steady futures.

Mentioned: , ,

Susan Dziubinski: Hi, I'm Susan Dziubinski from There's a lot to like about stocks with growing dividends. Not only do dividend growth stocks pay out income on a regular basis, but they also tend to be highly profitable, financially healthy businesses. Today, we're taking a look at three stocks that were recently added to the Morningstar Dividend Growth Index, which consists of U.S. stocks with a history of consistently growing their dividends and a significant margin to continue to do so in the future.

Karen Andersen: Gilead is a wide moat biotech we cover at Morningstar. It's trading at about a 20% discount our $84 fair value estimate. It's best known for its dominant HIV franchise as well as hepatitis C treatments and cancer therapies. I think investors right now are concerned about where sales growth is going to be coming from in the future, as well as its late stage pipeline. If you look at our forecast, we've got very stable, growing HIV sales going forward through 2033. And this is really because of a new HIV drug they have, Biktarvy, that's just been launched and had a tremendous growth profile so far. We also think their pipeline, even though it is thinner than some other companies, it has very strong prospects for an arthritis drug that's going to be launching this year. So, that's a multibillion-dollar franchise.

Susan Dziubinski does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.